With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

By Sriparna Roy Dec 15 (Reuters) - Gilead Sciences said on Monday its experimental HIV treatment was found to be ...

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Dec 15 (Reuters) - Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

Zimbabwe is preparing to place at least 46 500 people on a long-acting HIV prevention drug early next year marking the country's first rollout of Lenacapavir a twice-yearly injectable that offers ...

The first deliveries of lenacapavir to the African continent represent a turning point in the fight against HIV.

Please provide your email address to receive an email when new articles are posted on . Twice-yearly lenacapavir injections reduced HIV infections by 96% in a phase 3 trial. Gilead Sciences will begin ...